Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
VTYX is expected to report earnings to rise 32.34% to -50 cents per share on November 12
Q3'25
Est.
$-0.50
Q2'25
Beat
by $0.08
Q1'25
Beat
by $0.10
Q4'24
Beat
by $0.13
Q3'24
Beat
by $0.02
The last earnings report on August 07 showed earnings per share of -37 cents, beating the estimate of -46 cents. With 173.03K shares outstanding, the current market capitalization sits at 199.96M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. VTYX showed earnings on August 07, 2025. You can read more about the earnings report here.